APO Research
Talk to an analyst

APO RESEARCH · REPORT

HIV and AIDS Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global HIV and AIDS Vaccine Market Outlook and Growth Opportunities 2026

27 December 2025190 pages

Choose your research edition.

Industry ResearchHIV and AIDS Vaccine Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal HIV and AIDS Vaccine Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal HIV and AIDS Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal HIV and AIDS Vaccine Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal HIV and AIDS Vaccine Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global HIV and AIDS Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for HIV and AIDS Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for HIV and AIDS Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for HIV and AIDS Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the HIV and AIDS Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the HIV and AIDS Vaccine market include HKUMed, Sanofi-Pasteur, Johnson and Johnson (Janssen), IAVI, Uvax Bio and AELIX Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global HIV and AIDS Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of HIV and AIDS Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents HIV and AIDS Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the HIV and AIDS Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

HIV and AIDS Vaccine Segment by Company

HKUMed

Sanofi-Pasteur

Johnson and Johnson (Janssen)

IAVI

Uvax Bio

AELIX Therapeutics

HIV and AIDS Vaccine Segment by Type

Preventive Vaccine

Therapeutic Vaccine

HIV and AIDS Vaccine Segment by Application

Viral Vector Vaccines

Nucleic Acid Vaccines (including mRNA Vaccines)

Recombinant Protein Vaccines

Other Vaccines

HIV and AIDS Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global HIV and AIDS Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions HIV and AIDS Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify HIV and AIDS Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze HIV and AIDS Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HIV and AIDS Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of HIV and AIDS Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HIV and AIDS Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the HIV and AIDS Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global HIV and AIDS Vaccine industry.

Chapter 3: Detailed analysis of HIV and AIDS Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of HIV and AIDS Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of HIV and AIDS Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. HIV and AIDS Vaccine Industry Trends Table 2. HIV and AIDS Vaccine Industry Drivers Table 3. HIV and AIDS Vaccine Industry Opportunities and Challenges Table 4. HIV and AIDS Vaccine Industry Restraints Table 5. Global HIV and AIDS Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global HIV and AIDS Vaccine Revenue Share by Company (2021-2026) Table 7. Global HIV and AIDS Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global HIV and AIDS Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global HIV and AIDS Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global HIV and AIDS Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global HIV and AIDS Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global HIV and AIDS Vaccine Company, Product Type & Application Table 13. Global HIV and AIDS Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global HIV and AIDS Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Preventive Vaccine Table 18. Significant Companies of Therapeutic Vaccine Table 19. Global HIV and AIDS Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global HIV and AIDS Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 21. Global HIV and AIDS Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 22. Global HIV and AIDS Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global HIV and AIDS Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global HIV and AIDS Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global HIV and AIDS Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global HIV and AIDS Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global HIV and AIDS Vaccine Sales Value Share by Type (2021-2026) Table 28. Global HIV and AIDS Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Viral Vector Vaccines Table 30. Significant Companies of Nucleic Acid Vaccines (including mRNA Vaccines) Table 31. Significant Companies of Recombinant Protein Vaccines Table 32. Significant Companies of Other Vaccines Table 33. Global HIV and AIDS Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global HIV and AIDS Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 35. Global HIV and AIDS Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 36. Global HIV and AIDS Vaccine Sales Volume Share by Application (2021-2026) Table 37. Global HIV and AIDS Vaccine Sales Volume Share by Application (2027-2032) Table 38. Global HIV and AIDS Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global HIV and AIDS Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global HIV and AIDS Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global HIV and AIDS Vaccine Sales Value Share by Application (2021-2026) Table 42. Global HIV and AIDS Vaccine Sales Value Share by Application (2027-2032) Table 43. Global HIV and AIDS Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global HIV and AIDS Vaccine Sales by Region (2021-2026) & (K Units) Table 45. Global HIV and AIDS Vaccine Sales Market Share by Region (2021-2026) Table 46. Global HIV and AIDS Vaccine Sales by Region (2027-2032) & (K Units) Table 47. Global HIV and AIDS Vaccine Sales Market Share by Region (2027-2032) Table 48. Global HIV and AIDS Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global HIV and AIDS Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global HIV and AIDS Vaccine Sales Value Share by Region (2021-2026) Table 51. Global HIV and AIDS Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global HIV and AIDS Vaccine Sales Value Share by Region (2027-2032) Table 53. Global HIV and AIDS Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global HIV and AIDS Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global HIV and AIDS Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global HIV and AIDS Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global HIV and AIDS Vaccine Sales by Country (2021-2026) & (K Units) Table 58. Global HIV and AIDS Vaccine Sales Market Share by Country (2021-2026) Table 59. Global HIV and AIDS Vaccine Sales by Country (2027-2032) & (K Units) Table 60. Global HIV and AIDS Vaccine Sales Market Share by Country (2027-2032) Table 61. Global HIV and AIDS Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global HIV and AIDS Vaccine Sales Value Market Share by Country (2021-2026) Table 63. Global HIV and AIDS Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global HIV and AIDS Vaccine Sales Value Market Share by Country (2027-2032) Table 65. HKUMed Company Information Table 66. HKUMed Business Overview Table 67. HKUMed HIV and AIDS Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. HKUMed HIV and AIDS Vaccine Product Portfolio Table 69. HKUMed Recent Development Table 70. Sanofi-Pasteur Company Information Table 71. Sanofi-Pasteur Business Overview Table 72. Sanofi-Pasteur HIV and AIDS Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Sanofi-Pasteur HIV and AIDS Vaccine Product Portfolio Table 74. Sanofi-Pasteur Recent Development Table 75. Johnson and Johnson (Janssen) Company Information Table 76. Johnson and Johnson (Janssen) Business Overview Table 77. Johnson and Johnson (Janssen) HIV and AIDS Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Johnson and Johnson (Janssen) HIV and AIDS Vaccine Product Portfolio Table 79. Johnson and Johnson (Janssen) Recent Development Table 80. IAVI Company Information Table 81. IAVI Business Overview Table 82. IAVI HIV and AIDS Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. IAVI HIV and AIDS Vaccine Product Portfolio Table 84. IAVI Recent Development Table 85. Uvax Bio Company Information Table 86. Uvax Bio Business Overview Table 87. Uvax Bio HIV and AIDS Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Uvax Bio HIV and AIDS Vaccine Product Portfolio Table 89. Uvax Bio Recent Development Table 90. AELIX Therapeutics Company Information Table 91. AELIX Therapeutics Business Overview Table 92. AELIX Therapeutics HIV and AIDS Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. AELIX Therapeutics HIV and AIDS Vaccine Product Portfolio Table 94. AELIX Therapeutics Recent Development Table 95. Key Raw Materials Table 96. Raw Materials Key Suppliers Table 97. HIV and AIDS Vaccine Distributors List Table 98. HIV and AIDS Vaccine Customers List Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. HIV and AIDS Vaccine Product Image Figure 2. Global HIV and AIDS Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global HIV and AIDS Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global HIV and AIDS Vaccine Sales (2021-2032) & (K Units) Figure 5. Global HIV and AIDS Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global HIV and AIDS Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Preventive Vaccine Image Figure 10. Therapeutic Vaccine Image Figure 11. Global HIV and AIDS Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global HIV and AIDS Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global HIV and AIDS Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global HIV and AIDS Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global HIV and AIDS Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global HIV and AIDS Vaccine Sales Value Share by Type (2021-2032) Figure 17. Viral Vector Vaccines Image Figure 18. Nucleic Acid Vaccines (including mRNA Vaccines) Image Figure 19. Recombinant Protein Vaccines Image Figure 20. Other Vaccines Image Figure 21. Global HIV and AIDS Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global HIV and AIDS Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global HIV and AIDS Vaccine Sales Volume Share by Application (2021-2032) Figure 24. Global HIV and AIDS Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global HIV and AIDS Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global HIV and AIDS Vaccine Sales Value Share by Application (2021-2032) Figure 27. Global HIV and AIDS Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global HIV and AIDS Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global HIV and AIDS Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global HIV and AIDS Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America HIV and AIDS Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. North America HIV and AIDS Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe HIV and AIDS Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Europe HIV and AIDS Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific HIV and AIDS Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific HIV and AIDS Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America HIV and AIDS Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. South America HIV and AIDS Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa HIV and AIDS Vaccine Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa HIV and AIDS Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. HIV and AIDS Vaccine Value Chain Figure 126. Manufacturing Cost Structure Figure 127. HIV and AIDS Vaccine Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Preventive Vaccine
  • Therapeutic Vaccine
Applications
  • Viral Vector Vaccines
  • Nucleic Acid Vaccines (including mRNA Vaccines)
  • Recombinant Protein Vaccines
  • Other Vaccines
Companies covered
  • HKUMed
  • Sanofi-Pasteur
  • Johnson and Johnson (Janssen)
  • IAVI
  • Uvax Bio
  • AELIX Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global HIV and AIDS Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global HIV and AIDS Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global HIV and AIDS Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 HIV and AIDS Vaccine Market Dynamics
  1. 2.1 HIV and AIDS Vaccine Industry Trends
  2. 2.2 HIV and AIDS Vaccine Industry Drivers
  3. 2.3 HIV and AIDS Vaccine Industry Opportunities and Challenges
  4. 2.4 HIV and AIDS Vaccine Industry Restraints
3 HIV and AIDS Vaccine Market by Company
  1. 3.1 Global HIV and AIDS Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global HIV and AIDS Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global HIV and AIDS Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global HIV and AIDS Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global HIV and AIDS Vaccine Company Ranking (2024-2026)
  6. 3.6 Global HIV and AIDS Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global HIV and AIDS Vaccine Company Product Type and Application
  8. 3.8 Global HIV and AIDS Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global HIV and AIDS Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 HIV and AIDS Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 HIV and AIDS Vaccine Market by Type
  1. 4.1 HIV and AIDS Vaccine Type Introduction
  2. 4.1.1 Preventive Vaccine
  3. 4.1.2 Therapeutic Vaccine
  4. 4.2 Global HIV and AIDS Vaccine Sales Volume by Type
  5. 4.2.1 Global HIV and AIDS Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global HIV and AIDS Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global HIV and AIDS Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global HIV and AIDS Vaccine Sales Value by Type
  9. 4.3.1 Global HIV and AIDS Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global HIV and AIDS Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global HIV and AIDS Vaccine Sales Value Share by Type (2021-2032)
5 HIV and AIDS Vaccine Market by Application
  1. 5.1 HIV and AIDS Vaccine Application Introduction
  2. 5.1.1 Viral Vector Vaccines
  3. 5.1.2 Nucleic Acid Vaccines (including mRNA Vaccines)
  4. 5.1.3 Recombinant Protein Vaccines
  5. 5.1.4 Other Vaccines
  6. 5.2 Global HIV and AIDS Vaccine Sales Volume by Application
  7. 5.2.1 Global HIV and AIDS Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global HIV and AIDS Vaccine Sales Volume by Application (2021-2032)
  9. 5.2.3 Global HIV and AIDS Vaccine Sales Volume Share by Application (2021-2032)
  10. 5.3 Global HIV and AIDS Vaccine Sales Value by Application
  11. 5.3.1 Global HIV and AIDS Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global HIV and AIDS Vaccine Sales Value by Application (2021-2032)
  13. 5.3.3 Global HIV and AIDS Vaccine Sales Value Share by Application (2021-2032)
6 HIV and AIDS Vaccine Regional Sales and Value Analysis
  1. 6.1 Global HIV and AIDS Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global HIV and AIDS Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global HIV and AIDS Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global HIV and AIDS Vaccine Sales by Region (2027-2032)
  5. 6.3 Global HIV and AIDS Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global HIV and AIDS Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global HIV and AIDS Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global HIV and AIDS Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global HIV and AIDS Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America HIV and AIDS Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America HIV and AIDS Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe HIV and AIDS Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe HIV and AIDS Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific HIV and AIDS Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific HIV and AIDS Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America HIV and AIDS Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America HIV and AIDS Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa HIV and AIDS Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa HIV and AIDS Vaccine Sales Value Share by Country, 2025 VS 2032
7 HIV and AIDS Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global HIV and AIDS Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global HIV and AIDS Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global HIV and AIDS Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global HIV and AIDS Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global HIV and AIDS Vaccine Sales by Country (2027-2032)
  6. 7.4 Global HIV and AIDS Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global HIV and AIDS Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global HIV and AIDS Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt HIV and AIDS Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt HIV and AIDS Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt HIV and AIDS Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 HKUMed
  2. 8.1.1 HKUMed Company Information
  3. 8.1.2 HKUMed Business Overview
  4. 8.1.3 HKUMed HIV and AIDS Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 HKUMed HIV and AIDS Vaccine Product Portfolio
  6. 8.1.5 HKUMed Recent Developments
  7. 8.2 Sanofi-Pasteur
  8. 8.2.1 Sanofi-Pasteur Company Information
  9. 8.2.2 Sanofi-Pasteur Business Overview
  10. 8.2.3 Sanofi-Pasteur HIV and AIDS Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi-Pasteur HIV and AIDS Vaccine Product Portfolio
  12. 8.2.5 Sanofi-Pasteur Recent Developments
  13. 8.3 Johnson and Johnson (Janssen)
  14. 8.3.1 Johnson and Johnson (Janssen) Company Information
  15. 8.3.2 Johnson and Johnson (Janssen) Business Overview
  16. 8.3.3 Johnson and Johnson (Janssen) HIV and AIDS Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Johnson and Johnson (Janssen) HIV and AIDS Vaccine Product Portfolio
  18. 8.3.5 Johnson and Johnson (Janssen) Recent Developments
  19. 8.4 IAVI
  20. 8.4.1 IAVI Company Information
  21. 8.4.2 IAVI Business Overview
  22. 8.4.3 IAVI HIV and AIDS Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 IAVI HIV and AIDS Vaccine Product Portfolio
  24. 8.4.5 IAVI Recent Developments
  25. 8.5 Uvax Bio
  26. 8.5.1 Uvax Bio Company Information
  27. 8.5.2 Uvax Bio Business Overview
  28. 8.5.3 Uvax Bio HIV and AIDS Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Uvax Bio HIV and AIDS Vaccine Product Portfolio
  30. 8.5.5 Uvax Bio Recent Developments
  31. 8.6 AELIX Therapeutics
  32. 8.6.1 AELIX Therapeutics Company Information
  33. 8.6.2 AELIX Therapeutics Business Overview
  34. 8.6.3 AELIX Therapeutics HIV and AIDS Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 AELIX Therapeutics HIV and AIDS Vaccine Product Portfolio
  36. 8.6.5 AELIX Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 HIV and AIDS Vaccine Value Chain Analysis
  2. 9.1.1 HIV and AIDS Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 HIV and AIDS Vaccine Sales Mode & Process
  6. 9.2 HIV and AIDS Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 HIV and AIDS Vaccine Distributors
  9. 9.2.3 HIV and AIDS Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst